Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system

Pituitary

Volumn 18, Issue 4, 2015, Pages 500-508

  Nunes, V S ^a   Correa, J M S ^a   Puga, M E S ^b   Silva, E M K ^b   Boguszewski, C L ^c  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Acromegaly; Meta analysis; Somatostatin analogues; Systematic review

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN; SOMATOSTATIN DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYCLOPEPTIDE; HUMAN GROWTH HORMONE; SOMATOMEDIN C; SOMATOSTATIN;

ACROMEGALY; ADENOMA; AGE; ARTICLE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE CONTROL; GENDER; HEALTH CARE COST; HUMAN; HYPERTENSION; LENGTH OF STAY; META ANALYSIS (TOPIC); MORTALITY; POSTOPERATIVE COMPLICATION; PREMEDICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SYSTEMATIC REVIEW; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; GLUCOSE TOLERANCE TEST; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; META ANALYSIS; METABOLISM; NEOADJUVANT THERAPY; NEUROSURGERY; PREOPERATIVE CARE;

ADENOMA; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; GLUCOSE TOLERANCE TEST; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NEOADJUVANT THERAPY; NEUROSURGICAL PROCEDURES; OCTREOTIDE; PEPTIDES, CYCLIC; PREOPERATIVE CARE; QUALITY OF LIFE; SOMATOSTATIN;

EID: 84932198389     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-014-0602-9     Document Type: Article

References (31)

1. Melmed S, Colao A, Barkan A et al (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509–1517. doi:10.1210/jc.2008-2421
2. Melmed S (2006) Acromegaly. N Engl J Med 355:2558–2573. doi:10.1111/j.1365-2036.2011.04905.x
3. Vieira Neto L, Abucham J, de Araujo LA et al (2011) Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil. Arq Bras Endocrinol Metabol 55:91–105. doi:10.1590/S0004-27302011000200001
4. Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical “cure”. Eur J Endocrinol 152:379–387. doi:10.1530/eje.1.01863
5. Wass JA, Turner HE, Adams CB, HE, Adams CB (1999) The importance of locating a good pituitary surgeon. Pituitary 2:51–54
6. Stevenaert A, Harris AG, Kovacs K, Beckers A (1992) Presurgical octreotide treatment in acromegaly. Metabolism 51–58
7. Abe T, Lüdecke DK (2001) Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 145:137–145. doi:10.1530/eje.0.1450137
8. Colao A, Ferone D, Cappabianca P et al (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82:3308–3314. doi:10.1097/00019616-199803000-00020
9. Barkan AL, Lloyd RV, Chandler WF et al (1988) Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67:1040–1048
10. Biermasz NR, van Dulken H, Roelfsema F (1999) Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 84:3551–3555
11. Kristof RA, Stoffel-Wagner B, Klingmüller D, Schramm J (1999) Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochir (Wien) 141:399–405. doi:10.1007/s007010050316
12. The Cochrane Collaboration (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Version 510 [updated March 2011] Cochrane Collab. www.cochrane-handbook.org
13. Guyatt GH, Oxman AD, Kunz R et al (2008) What is “quality of evidence” and why is it important to clinicians? BMJ Br Med J 336:995–998. doi:10.1136/bmj.39490.551019.BE
14. Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383–394. doi:10.1016/j.jclinepi.2010.04.026
15. Carlsen SM, Lund-Johansen M, Schreiner T et al (2008) Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 93:2984–2990. doi:10.1210/jc.2008-0315
16. Shen M, Shou X, Wang Y et al (2010) Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr J 57:1035–1044. doi:10.1507/endocrj.K10E-203
17. Mao Z, Zhu Y, Tang H et al (2010) Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol 162:661–666. doi:10.1530/EJE-09-0908
18. Li Z-Q, Quan Z, Tian H-L, Cheng M (2012) Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma. J Int Med Res 40:517–524. doi:10.1177/147323001204000213
19. Carlsen SM, Svartberg J, Schreiner T et al (2011) Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clin Endocrinol (Oxf) 74:736–743. doi:10.1111/j.1365-2265.2011.03982.x
20. Losa M, Mortini P, Urbaz L et al (2006) Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg 104:899–906. doi:10.3171/jns.2006.104.6.899
21. Plöckinger U, Quabbe H-J (2005) Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochir (Wien) 147:485–493; discussion 493. doi:10.1007/s00701-005-0511-9
22. Waśko R, Ruchała M, Sawicka J et al (2000) Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly. J Endocrinol Invest 23:12–18
23. Ezzat S, Kontogeorgos G, Redelmeier DA et al (1995) In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 133:686–690. doi:10.1530/eje.0.1330686
24. Thapar K, Kovacs KT, Stefaneanu L et al (1997) Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial. Mayo Clin Proc 72:893–900. doi:10.4065/72.10.893
25. Cannavò S, Squadrito S, Curtò L et al (2001) Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma. Horm Metab Res 33:618–624. doi:10.1055/s-2001-17910
26. Giustina A, Chanson P, Kleinberg D et al (2014) Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 10:243–248. doi:10.1038/nrendo.2014.21
27. Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S et al (2013) Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS One. doi:10.1371/journal.pone.0061523
28. Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 7. Rating the quality of evidence—inconsistency. J Clin Epidemiol 64:1294–1302. doi:10.1016/j.jclinepi.2011.03.017
29. Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 8. Rating the quality of evidence—indirectness. J Clin Epidemiol 64:1303–1310. doi:10.1016/j.jclinepi.2011.04.014
30. Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines 6. Rating the quality of evidence—imprecision. J Clin Epidemiol 64:1283–1293. doi:10.1016/j.jclinepi.2011.01.012
31. Guyatt GH, Oxman AD, Montori V et al (2011) GRADE guidelines: 5. Rating the quality of evidence—publication bias. J Clin Epidemiol 64:1277–1282. doi:10.1016/j.jclinepi.2011.01.011